Illumina, Inc. (ILMN)
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.
Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 12:00 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect. Good morning, everyone.
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the world's largest genetic database.
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Grail: What Lies Ahead After the Illumina Spin-Off
This spotlight on the ROBO Global Healthcare Technology and Innovation Index highlights Grail (GRAL), a standout within the Genomics subsector. It is a key component of the $53.6 million ROBO Global Healthcare Technology and Innovation ETF (HTEC).
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Interpreting Illumina (ILMN) International Revenue Trends
Explore how Illumina's (ILMN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Illumina: Q3 Confirms Improving Fundamentals
Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally.
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
